Oncotarget

Research Papers:

Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma

Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Yan-Ming Jiang, Jia-Lin Ma, Song Qu, Ling Li, Long Chen and Xiao-Dong Zhu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:46211-46218. https://doi.org/10.18632/oncotarget.17582

Metrics: PDF 1198 views  |   HTML 1625 views  |   ?  


Abstract

Xin-Bin Pan1, Shi-Ting Huang1, Kai-Hua Chen1, Yan-Ming Jiang1, Jia-Lin Ma1, Song Qu1, Ling Li1, Long Chen1 and Xiao-Dong Zhu1

1Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China

Correspondence to:

Xiao-Dong Zhu, email: [email protected]

Keywords: nasopharyngeal carcinoma, quality of life, intensity-modulated radiotherapy, two-dimensional conventional radiotherapy

Received: January 02, 2017     Accepted: April 03, 2017     Published: May 03, 2017

ABSTRACT

Two-dimensional conventional radiotherapy (2D-CRT) and intensity-modulated radiotherapy (IMRT) are effective for control of nasopharyngeal carcinoma (NPC). The purpose of this study was to compare the quality of life (QoL) of stage II NPC patients treated with 2D-CRT versus IMRT. We conducted a cross-sectional study of 106 patients with stage II NPC treated with 2D-CRT (n = 47) versus IMRT (n = 59) between June 2008 and June 2013. For all subjects, disease-free survival was more than 3 years. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questions and the Head and Neck 35 (EORTC QLQ-H&N35) questions. Patients receiving IMRT with or without concurrent chemotherapy had better outcomes in head and neck related symptoms and general aspects of QoL than those receiving 2D-CRT with or without concurrent chemotherapy. Thus, IMRT improves the QoL of patients with stage II NPC as compared to 2D-CRT.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17582